Pharsight

Hetlioz patents expiration

HETLIOZ IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5856529 VANDA PHARMS INC Benzofuran and dihydrobenzofuran melatonergic agents
Dec, 2022

(1 year, 6 months ago)

US10071977 VANDA PHARMS INC Highly purifid pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11566011 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US10829465 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

US11760740 VANDA PHARMS INC Highly purified pharmaceutical grade tasimelteon
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855241 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

USRE46604 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9060995 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10449176 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11918556 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11826339 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11850229 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11833130 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10945988 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US8785492 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11633377 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US9549913 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11285129 VANDA PHARMS INC Treatment of circadian rhythm disorders
Jan, 2033

(8 years from now)

US11918557 VANDA PHARMS INC Treatment of circadian rhythm disorders
Apr, 2033

(8 years from now)

US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders
May, 2034

(9 years from now)

US11141400 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10610511 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US11786502 VANDA PHARMS INC Method of treatment
Oct, 2034

(10 years from now)

US10376487 VANDA PHARMS INC Method of treatment
Jul, 2035

(11 years from now)

US11266622 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US10179119 VANDA PHARMS INC Method of treatment
Aug, 2035

(11 years from now)

US11759446 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Feb, 2041

(16 years from now)

Hetlioz is owned by Vanda Pharms Inc.

Hetlioz contains Tasimelteon.

Hetlioz has a total of 31 drug patents out of which 1 drug patent has expired.

Expired drug patents of Hetlioz are:

  • US5856529

Hetlioz was authorised for market use on 31 January, 2014.

Hetlioz is available in capsule;oral dosage forms.

Hetlioz can be used as treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food, treatment of non-24-hour sleep-wake disorder by administering tasimelteon, treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor, treatment of non-24 hour sleep-wake disorder by administering tasimelteon to patients with a smoking history, treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon, treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin, treatment of non-24 hour sleep-wake disorder by administering tasimelteon, treatment of non-24-hour sleep-wake disorder by avoiding the administration of tasimelteon with food, treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with fluvoxamine, treatment of non-24 hour sleep-wake disorder by orally administering 20mg of tasimelteon once daily before bedtime, treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors, treatment of non-24-hour sleep-wake disorder by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists, treatment of non-24-hour sleep-wake disorder.

Drug patent challenges can be filed against Hetlioz from 31 January, 2018.

The generics of Hetlioz are possible to be released after 21 February, 2041.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-330) Dec 01, 2027
Orphan Drug Exclusivity(ODE) Jan 31, 2021
New Indication(I-850) Dec 01, 2023
New Chemical Entity Exclusivity(NCE) Jan 31, 2019
Orphan Drug Exclusivity(ODE-59) Jan 31, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TASIMELTEON ingredient

NCE-1 date: 31 January, 2018

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of non-24 hour sleep-wake disorder by administering tasimelteon; Treatment of non-24 hour sleep-wake disorder by orally administering 20mg of tasimelteon once daily before bedtime; Treatment...

Dosage: CAPSULE;ORAL

How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage

HETLIOZ family patents

Family Patents